Get the Stockscreener App
16.21
2.35%
-0.39
After Hours:
16.21
Gh Research Plc stock is traded at $16.21, with a volume of 138.26K.
It is down -2.35% in the last 24 hours and up +28.65% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$16.60
Open:
$16.69
24h Volume:
138.26K
Relative Volume:
0.33
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-20.52
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
+2.92%
1M Performance:
+28.65%
6M Performance:
+11.79%
1Y Performance:
+84.00%
1-Day Range:
$16.00
$16.69
1-Week Range:
$15.48
$17.30
52-Week Range:
$7.98
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
16.21 | 1.03B | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
Market Pulse: Is GH Research PLC a turnaround storyJuly 2025 Price Swings & Consistent Income Trade Recommendations - baoquankhu1.vn
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A | What are the risks of holding GH Research PLCWeekly Investment Recap & Daily Risk Controlled Trade Plans - mfd.ru
GHRS: RBC Capital Raises Price Target to $40, Maintains 'Outperf - GuruFocus
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
GH Research stock price target raised to $40 from $33 at RBC Capital - Investing.com Nigeria
(GHRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
GH Research to Present at RBC Capital Markets Psychedelics Symposium - TipRanks
GH Research (NASDAQ:GHRS) Stock Price Down 7.5%Here's What Happened - MarketBeat
Aug Opening: Can GH Research PLC ride the EV waveWeekly Investment Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
GH Research (GHRS) Is Up 9.1% After FDA Lifts Clinical Hold On GH001 Depression Drug - simplywall.st
Aug Setups: Whats the profit margin of GH Research PLCJuly 2025 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
What is the dividend yield of GH Research PLCPortfolio Update Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
CEO Change: Is GH Research PLC a turnaround story2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is GH Research PLC stock undervalued right now2025 Key Highlights & Weekly High Momentum Picks - bollywoodhelpline.com
Aug Setups: Is GH Research PLC stock supported by strong fundamentalsJuly 2025 Summary & Verified Entry Point Detection - Bộ Nội Vụ
GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026 - TipRanks
How FDA’s Lifted Clinical Hold On GH001 At GH Research (GHRS) Has Changed Its Investment Story - Yahoo Finance
Responsive Playbooks and the GHRS Inflection - Stock Traders Daily
EBIT per share of GH Research Plc – FWB:1KA - TradingView — Track All Markets
GH Research PLC (GHRS) Stock Analysis: 109.70% Upside Potential Amid Promising Biotech Innovations - DirectorsTalk Interviews
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - MSN
Will GH Research PLC (1KA) stock profit from fiscal stimulusStability vs Neutral Overview & lightweight options for faster days - Улправда
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December - Sahm
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 IND - Sahm
Is GH Research PLC (1KA) stock protected from inflationTrade Ideas & Low Risk Entry Point Tips - Улправда
Why analysts maintain buy rating on GH Research PLC (1KA) stock2025 Market Overview & Low Risk Profit Maximizing Plans - Улправда
Risk Analysis: How institutional buying supports GH Research PLC stockTrend Reversal & High Accuracy Investment Entry Signals - ulpravda.ru
Published on: 2026-01-09 02:32:55 - Улправда
GH Research PLCOrdinary Shares (NQ: GHRS - FinancialContent
What dividend safety score for GH Research PLC stockEarnings Risk Report & Low Risk High Reward Trade Ideas - ulpravda.ru
How strong is GH Research PLC stock balance sheet2025 Valuation Update & Weekly High Conviction Ideas - Улправда
Quarterly Recap: What dividend safety score for GH Research PLC stock2025 Top Gainers & Weekly High Conviction Trade Ideas - ulpravda.ru
GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting - TipRanks
Why is GHRS stock rising today? - MSN
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 Trials - Yahoo Finance
Stock market today: S&P 500, Nasdaq futures rise, WTI fluctuates following US strike on Venezuela—GH Research, Vertiv Holdings, Nukkleus in focus - MSN
Why Is GHRS Stock Rising Today? - Asianet Newsable
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment - Asianet Newsable
What drives GH Research PLC stock priceDividend Reinvestment Plans & Outstanding Capital Tips - earlytimes.in
Will GH Research PLC (1KA) stock gain from green policies2026 world cup usa national team round of 32 playmakers pressing system odds analysis tactical review - Улправда
GH Research (NASDAQ:GHRS) Stock Price Down 9.2%Should You Sell? - MarketBeat
GH Research stock price target raised to $29 from $19 at Needham - Investing.com Nigeria
GH Research stock jumps as Canaccord raises price target on FDA hold lift - Investing.com Nigeria
GH Research stock price target raised to $29 from $19 at Needham By Investing.com - Investing.com South Africa
GH Research stock rises as FDA lifts clinical hold on GH001 By Investing.com - Investing.com South Africa
GH Research stock jumps as Canaccord raises price target on FDA hold lift By Investing.com - Investing.com South Africa
GH Research stock rises as FDA lifts clinical hold on GH001 - Investing.com Australia
GHRS Stock Sees Significant Price Target Increase by Needham | G - GuruFocus
GH Research (GHRS) Is Up 24.2% After FDA Lifts Hold On GH001 U.S. Trial Enrollment - simplywall.st
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):